Analysts see an interesting path ahead for Gilead Sciences, Inc. (NASDAQ:GILD), between exciting collaborative possibilities and its pipeline catalysts that have brought bullish …
In Vienna, Austria at the United European Gastroenterology Week (UEGW) Conference held from October 15th through the 19th, Celgene Corporation (NASDAQ:CELG) announced new …
Yesterday, Marinus Pharmaceuticals Inc (NASDAQ:MRNS) announced more complete data from the exploratory Phase II study in 11 children with uncontrolled seizures due to …
Jefferies analyst Brian Abrahams provides insight on shares of Gilead Sciences, Inc. (NASDAQ:GILD) on the heels of hosting a dinner with a leading …
Biogen Inc (NASDAQ:BIIB) indicated in its brief PR update yesterday that its pipeline drug aducanumab, the firm’s investigational treatment for early Alzheimer’s disease …
Jefferies analyst Brian Abrahams is out with a research report on shares of Gilead Sciences, Inc. (NASDAQ:GILD), reiterating a Hold rating on GILD, …
Analyst Brian Abrahams from Jefferies provides his insight on the different drug developments concerning Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG).
In a research report issued this morning, analyst Brian Abrahams of Wells Fargo maintained an Outperform rating on Gilead Sciences (NASDAQ:GILD), as GILD’s Harvoni/Sovaldi IMS data weekended …
